載入中
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
前收盤價
US$8.19
+US$0.63 · +8.33%
盤中時間採用ET。市場資料可能有所延遲。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日內區間
目前US$8.19
52週區間
目前US$8.19
盤中時間採用ET。市場資料可能有所延遲。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日內區間
目前US$8.19
52週區間
目前US$8.19
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 8198.3萬 USD | 8004.6萬 USD | 8321.5萬 USD | 7125.5萬 USD | 6111.5萬 USD |
| 銷售、一般及管理費用 | 2124.5萬 USD | 1800.6萬 USD | 1600.8萬 USD | 1526.3萬 USD | 1330萬 USD |
| 營業費用 | 1.03億 USD | 9805.2萬 USD | 9922.3萬 USD | 1.19億 USD | 9166.5萬 USD |
| 利息收入 | 104萬 USD | 339萬 USD | 307.5萬 USD | 104.1萬 USD | 6.6萬 USD |
| 利息支出 | — | — | — | 104.1萬 USD | — |
| 折舊和攤銷 | 16.8萬 USD | 13.4萬 USD | 11.1萬 USD | 7.7萬 USD | 8.5萬 USD |
| 營業利益 | −1.03億 USD | −9805.2萬 USD | −9922.3萬 USD | −1.19億 USD | −9166.5萬 USD |
| 淨利 | −9717.2萬 USD | −1.01億 USD | −9361.2萬 USD | −1.2億 USD | −9294.5萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$22.13
上漲空間 170.21%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年4月27日 | 1:10 | — | — |
股票分割 | 2019年4月15日 | 1:40 | — | — |
已生效 2026年4月27日
1:10
已生效 2019年4月15日
1:40
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI630.56萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF251.61萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC32.63萬0.02%13.17億 USD0.60%US$183+0.11%
Simplify Propel Opportunities ETFSURI25.16萬0.33%7606.44萬 USD2.82%US$17.06-0.14%
ALPS Medical Breakthroughs ETFSBIO13.88萬0.07%1.91億 USD0.50%US$55.04+2.03%
Avantis U.S. Small Cap Equity ETFAVSC13.25萬—30.82億 USD0.25%US$69.98+0.03%
Invesco NASDAQ Future Gen 200 ETFQQQS6.18萬0.27%2275.83萬 USD0.20%US$42.145+1.39%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCSimplify Propel Opportunities ETFSURIALPS Medical Breakthroughs ETFSBIOAvantis U.S. Small Cap Equity ETFAVSCInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
